1Ling R, Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol, 1999,80:601-606.
2Gutfreund KS, Williams M, George R, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol, 2000,33:469-475.
3Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 1998,339:61-68.
4Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 2000,119:172-180.
5Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.Hepatology, 2000,31: 1318-1326.
6Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 2001,33: 1527-1532.
7Liaw YF. Therapy in the 21th century; Hepatitis B. APASL, IASL and ISH joint postgraduate course, 2000: 17-20.
8Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology, 1999,30: 567-572.
10Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology, 2000, 32:1145-1153.
10Rosenau J, Bahr M, Tillmann HL, et al. Lamivudine and low dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol, 2001, 34(6):895-902.
